StockData

Nanobiotix vs Zentalis Pharmaceuticals

NBTX and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NBTX and ZNTL compare

Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 3 for Nanobiotix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNBTXZNTL
Size and price
Market cap–$107M
Share price$27.45$1.49
Change, 1 year32.0%12.0%
Change, 5 years225%−98.0%
Beta (5Y)0.685.80
Employees97106
StockData Score
Total score36 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/B–0.7×
FCF yield–−120%
Growth
Revenue growth, 5Y average67.0%–
Profitability
Operating margin−33.2%–
Net margin−73.5%–
FCF margin−104%–
Return on equity–−66.7%
Financial health
Debt / equity–0.00
Interest coverage−0.7×–
Current ratio1.444.82 (better)
Altman Z-score–−8.91
Piotroski F-score4 (better)1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions12.0%66.1%
Held by insiders0.00%58.0%
Insider net buying, 12 months–$12.8M
Short interest, % of float–16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.